THE RESEARCH RECESSION: 12 years of Anesthesiology progress in question

Over the past 12 years, anesthesiologist Scott Reuben revolutionized the way physicians provide pain relief to patients undergoing orthopedic surgery for everything from torn ligaments to worn-out hips. (Brendan Borrell, Scientific American) Rueben’s drug studies were responsible for convincing orthopedic surgeons to move away from the first generation of non-steroid anti-inflammatory drugs to a new method, known as COX2 inhibitors. He claimed that these new drugs, made popular under the names Vioxx, Celebrex, and Bextra, in combination with anticonvulsants could be effective in decreasing postoperative pain and reduce the use of addictive … [Read more...]

Cigarette Companies and Their Red Handed Researchers

In 2006, a study by Dr. Claudia I. Henshke of the Weill Medical College at Cornell University shocked the medical professional world by reporting that the widespread use of CT scans could help prevent 80% of lung cancer deaths. The study was published in the renowned New England Journal of Medicine, and sent shock waves of hope through the medical profession. Unfortunately, the good news would be tainted by the discovery of a crippling conflict of interest: The study was funded almost entirely by the cigarette industry. After Ms. Henshke reported her study to the Accreditation Council for Continuing Medical Education, an investigation … [Read more...]

The Secret Relationship of Medical Researchers and Pharmaceutical Companies

Finally, congress is investigating the giant pharmaceutical company’s corrupt research practices.  In the drug business, promoting health and safety should be priority number one.  Unfortunately, it is merely a distant second.  In the pharmaceutical industry, making money supersedes science. Some even go as far as claiming that drug makers have become a billion dollar empire not because of research and science, but rather from slick marketing and deceit.  This claim has some validity since the drug companies spend almost twice as much on the marketing of their drugs then on the development of their drugs.  Some also argue that many drugs … [Read more...]